Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Coagulation Factor III

Coagulation Factor III

Brief Information

Name:Tissue factor
Target Synonym:Coagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data


Anti-TF mAb immobilized on CM5 Chip can bind Human Tissue Factor, Fc Tag (Cat. No. TF3-H5253) with an affinity constant of 2.38 nM as determined in SPR assay (Biacore T200) (Routinely tested).


Anti-TF mAb immobilized on CM5 Chip via anti-human IgG Fc antibody can bind Human Tissue Factor, His Tag (Cat. No. TF3-H52H5) with an affinity constant of 1.52 nM as determined in SPR assay (Biacore T200) (Routinely tested).

Synonym Name

Coagulation Factor III,Tissue Factor,TF,F3,CD142


Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tisotumab vedotin TF-011-MMAE Approved Genmab HuMax-TF, TIVDAK United States Uterine Cervical Neoplasms Seagen Inc 2021-09-20 Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
XB-002 ICON-2; XB-002 Phase 1 Clinical Iconic Therapeutics Solid tumours; Urogenital Neoplasms Details
ALT-836 cH-36; ALT-836; TNX-832 Sunol Molecular Corp Details
MORAb-066 MORAb-066 Janssen Global Services Llc Details
hI-con1 ICON-1; hI-con1 Yale University Details
Recombinant NAPc2 AB-201 Phase 3 Clinical Dendreon Uk Ltd Coronavirus Disease 2019 (COVID-19) Details
MRG004A MRG004A Phase 2 Clinical Shanghai Miracogen Inc Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message